Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Editing02:23

RNA Editing

9.1K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.1K
RACE - Rapid Amplification of cDNA Ends02:35

RACE - Rapid Amplification of cDNA Ends

6.4K
Rapid Amplification of cDNA Ends, or RACE, is one of the most effective methods to obtain a full-length cDNA from an mRNA sequence between a known internal region to the unknown sequence at the 5’ or 3’ end. The unknown region is cloned in the cDNA by a gene-specific primer that binds the known end, and a hybrid primer that attaches a predefined anchor sequence to the unknown end of the cDNA. The sequence in between is amplified by PCR with an anchor primer and a gene-specific...
6.4K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

7.1K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Engineering TadA ortholog-derived cytosine base editor without motif preference and adenosine activity limitation.

Nature communications·2024
Same author

Engineering TadA ortholog-derived cytosine base editor without motif preference and adenosine activity limitation.

Nature communications·2024
Same author

Repurposing Type I-A CRISPR-Cas3 for a robust diagnosis of human papillomavirus (HPV).

Communications biology·2024
Same author

Development of deaminase-free T-to-S base editor and C-to-G base editor by engineered human uracil DNA glycosylase.

Nature communications·2024
Same author

Engineering a transposon-associated TnpB-ωRNA system for efficient gene editing and phenotypic correction of a tyrosinaemia mouse model.

Nature communications·2024
Same author

Development of miniature base editors using engineered IscB nickase.

Nature methods·2023

Related Experiment Video

Updated: Aug 1, 2025

A Nonsequencing Approach for the Rapid Detection of RNA Editing
08:50

A Nonsequencing Approach for the Rapid Detection of RNA Editing

Published on: April 21, 2022

2.6K

Develop a Compact RNA Base Editor by Fusing ADAR with Engineered EcCas6e.

Xing Wang1, Renxia Zhang2, Dong Yang2

  • 1HuidaGene Therapeutics Co. Ltd., 6th Floor, Unit 3, Building 5, No. 160 Basheng Road, Pudong New Area, Shanghai, 200131, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|April 25, 2023
PubMed
Summary
This summary is machine-generated.

A new compact RNA base editor (ceRBE) enables efficient adenine-to-inosine and cytidine-to-uridine conversions in cells and mice. This technology shows promise for treating genetic diseases like Duchenne muscular dystrophy.

Keywords:
CRISPRRNA base editinggene therapy

More Related Videos

Efficient PAM-Less Base Editing for Zebrafish Modeling of Human Genetic Disease with zSpRY-ABE8e
07:31

Efficient PAM-Less Base Editing for Zebrafish Modeling of Human Genetic Disease with zSpRY-ABE8e

Published on: February 17, 2023

1.2K
RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes
09:19

RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes

Published on: July 22, 2014

8.5K

Related Experiment Videos

Last Updated: Aug 1, 2025

A Nonsequencing Approach for the Rapid Detection of RNA Editing
08:50

A Nonsequencing Approach for the Rapid Detection of RNA Editing

Published on: April 21, 2022

2.6K
Efficient PAM-Less Base Editing for Zebrafish Modeling of Human Genetic Disease with zSpRY-ABE8e
07:31

Efficient PAM-Less Base Editing for Zebrafish Modeling of Human Genetic Disease with zSpRY-ABE8e

Published on: February 17, 2023

1.2K
RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes
09:19

RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes

Published on: July 22, 2014

8.5K

Area of Science:

  • Molecular Biology
  • Gene Editing Technologies
  • Biotechnology

Background:

  • CRISPR-Cas13 (dCas13) base editors facilitate RNA modifications but are limited by large protein size for in vivo use.
  • Developing smaller, efficient RNA base editors is crucial for expanding therapeutic applications.

Purpose of the Study:

  • To develop a compact and highly efficient RNA base editor (ceRBE) for in vivo applications.
  • To assess the editing efficiency and off-target effects of ceRBE.
  • To evaluate ceRBE's therapeutic potential in a Duchenne muscular dystrophy model.

Main Methods:

  • Replaced large dCas13 with a small EcCas6e protein (199 amino acids) to create ceRBE.
  • Optimized ceRBE for toxicity and editing efficiency.
  • Tested ceRBE in HEK293T cells and a humanized mouse model of Duchenne muscular dystrophy (DMD) via AAV delivery.

Main Results:

  • ceRBE achieved efficient adenine-to-inosine (A-to-I) and cytidine-to-uridine (C-to-U) base editing in HEK293T cells with low transcriptome off-target effects.
  • Demonstrated efficient repair of the DMD Q1392X mutation (68.3±10.1%) in a mouse model.
  • Restored gene product expression in the DMD mouse model.

Conclusions:

  • The compact ceRBE exhibits high in vivo editing efficiency and low off-target activity.
  • ceRBE holds significant potential for the treatment of genetic diseases.
  • This technology represents a promising advancement in RNA base editing therapeutics.